Loading...
OTCM
MSCLF
Market cap54mUSD
Dec 05, Last price  
0.48USD
1D
3.06%
1Q
2.09%
Jan 2017
-24.08%
IPO
-86.08%
Name

Satellos Bioscience Inc

Chart & Performance

D1W1MN
OTCM:MSCLF chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
82.89%
Rev. gr., 5y
%
Revenues
0k
000025,0000000
Net income
-16m
L+40.33%
-1,794,921-1,489,923-1,237,308-1,702,623-1,938,235-1,578,530-15,505,652-11,322,437-15,889,000
CFO
-15m
L+153.81%
-3,095,380-1,332,713-1,220,941-1,104,497-2,237,605-1,659,982-5,033,711-5,713,347-14,501,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
IPO date
Dec 01, 2006
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT